Purple Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Purple Biotech wird voraussichtlich ein Umsatzwachstum verzeichnen at 95.3% per annum.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	17.0%
Wachstumsrate der Einnahmen	95.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	19 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

If You Had Bought Purple Biotech's (TLV:KTOV) Shares Five Years Ago You Would Be Down 90%

Dec 21

Gewinn- und Umsatzwachstumsprognosen

TASE:PPBT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	N/A	-15	N/A	1
12/31/2025	N/A	N/A	-7	N/A	1
12/31/2024	N/A	N/A	-2	N/A	1
6/30/2024	N/A	-16	-18	-18	N/A
3/31/2024	N/A	-19	-19	-19	N/A
12/31/2023	N/A	-20	-20	-20	N/A
9/30/2023	N/A	-21	-19	-19	N/A
6/30/2023	N/A	-21	-19	-19	N/A
3/31/2023	N/A	-19	-18	-18	N/A
12/31/2022	N/A	-22	-17	-17	N/A
9/30/2022	N/A	-20	-17	-16	N/A
6/30/2022	N/A	-19	-16	-16	N/A
3/31/2022	N/A	-19	-17	-17	N/A
12/31/2021	N/A	-18	-15	-15	N/A
9/30/2021	N/A	-13	N/A	N/A	N/A
6/30/2021	-1	-11	-16	-16	N/A
3/31/2021	1	-21	N/A	N/A	N/A
12/31/2020	N/A	-29	-12	-12	N/A
9/30/2020	1	-30	-10	-10	N/A
6/30/2020	1	-31	-8	-8	N/A
3/31/2020	1	-18	-7	-7	N/A
12/31/2019	N/A	-5	-6	-6	N/A
9/30/2019	1	-4	-6	-6	N/A
6/30/2019	1	-3	-7	-7	N/A
3/31/2019	1	-4	-8	-8	N/A
12/31/2018	1	-5	-8	-8	N/A
9/30/2018	1	-8	-8	-8	N/A
6/30/2018	1	-11	-7	-7	N/A
3/31/2018	1	-12	N/A	-8	N/A
12/31/2017	0	-12	N/A	-9	N/A
9/30/2017	0	-14	N/A	-9	N/A
6/30/2017	N/A	-15	N/A	-9	N/A
3/31/2017	N/A	-14	N/A	-7	N/A
12/31/2016	N/A	-12	N/A	-6	N/A
9/30/2016	N/A	-9	N/A	-5	N/A
6/30/2016	N/A	-6	N/A	-4	N/A
3/31/2016	N/A	-5	N/A	-4	N/A
12/31/2015	N/A	-4	N/A	-3	N/A
9/30/2015	N/A	-4	N/A	-3	N/A
6/30/2015	N/A	-4	N/A	-3	N/A
3/31/2015	N/A	-5	N/A	-3	N/A
12/31/2014	N/A	-5	N/A	-5	N/A
9/30/2014	N/A	-5	N/A	-4	N/A
6/30/2014	N/A	-6	N/A	-3	N/A
3/31/2014	N/A	-4	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von PPBT über der Sparquote liegt (2.5%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von PPBT schneller wachsen werden als der Markt IL

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von PPBT in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: PPBT wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: PPBT wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von PPBT in 3 Jahren voraussichtlich hoch sein wird

Purple Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Purple Biotech Ltd. Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Purple Biotech Presents New Data for Its Novel Tri-Specific T Cell and Nk Cell Engagers Antibody Platform, Captn-3, At the Eortc-Nci-Aacr Symposium on Molecular Targets and Cancer Therapeutics

New major risk - Shareholder dilution

New major risk - Market cap size

High number of new directors

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule

Purple Biotech Ltd, Annual General Meeting, Aug 08, 2024

Purple Biotech Ltd. Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Purple Biotech Ltd Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and Other Efficacy Endpoints in Pancreatic Cancer

New major risk - Financial position

New major risk - Financial position

Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology

We're A Little Worried About Purple Biotech's (TLV:PPBT) Cash Burn Rate

New minor risk - Financial position

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Purple Biotech Ltd. Announces Executive Changes

Purple Biotech Ltd. Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Purple Biotech Ltd. has filed a Follow-on Equity Offering in the amount of $5.117393 million.

New major risk - Shareholder dilution

Can Purple Biotech (TLV:PPBT) Afford To Invest In Growth?

New minor risk - Share price stability

Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action

Purple Biotech Ltd. Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

New major risk - Financial position

Will Purple Biotech (TLV:PPBT) Spend Its Cash Wisely?

Purple Biotech Ltd. Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Purple Biotech Ltd., Annual General Meeting, Jun 15, 2023

High number of new directors

Here's Why We're Watching Purple Biotech's (TLV:PPBT) Cash Burn Situation

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of Cm24 Phase 2 Clinical Trial

Purple Biotech Ltd. (TASE:PPBT) agreed to acquire Immunorizon.

Is Purple Biotech (TLV:PPBT) In A Good Position To Deliver On Growth Plans?

Purple Biotech Ltd. Appoints Lior Fhima as Chief Financial Officer

Purple Biotech Ltd. Ordinary Shares to Be Deleted from OTC Equity

Is Purple Biotech (TLV:PPBT) In A Good Position To Deliver On Growth Plans?

Purple Biotech Ltd., Annual General Meeting, Aug 25, 2022

Purple Biotech Ltd. Announces Chief Executive Officer Changes

Purple Biotech Ltd. Announces Positive Interim Safety and Efficacy Data from the Phase 1 Study of NT219 in Adults with Advanced Solid Tumors

Purple Biotech Ltd. Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile

Purple Biotech Ltd. Announces the Initiation of Phase 2 Study for Cm24 in 2L PDAC Patients

Purple Biotech Ltd. Presents Positive Interim Phase 1B Study Results for CM24 At the American Association of Cancer Research 2022 Annual Meeting

Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans

Companies Like Purple Biotech (TLV:PPBT) Are In A Position To Invest In Growth

Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of Multiple Cancers Supporting Potential Expansion of Clinical Program

Purple Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update

Purple Biotech Ltd Presents New Clinical Data from Nt219 At the 2021

Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans

Purple Biotech Ltd. to Present New Data from the Ongoing Phase 1/2 Clinical Trial of NT219

Purple Biotech Ltd. Announces Initiation of Phase 1B/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers

Full year 2020 earnings released: US$0.24 loss per share

Purple Biotech Ltd. Appoints Robert Gagnon to Its Board of Directors

Revenue misses expectations

Full year 2020 earnings released

We Think Purple Biotech (TLV:PPBT) Can Afford To Drive Business Growth

New 90-day high: ₪2.13

If You Had Bought Purple Biotech's (TLV:KTOV) Shares Five Years Ago You Would Be Down 90%

New 90-day low: ₪1.34

Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb

Kitov Pharma Ltd Announces New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference

New 90-day low - ₪1.48

Kitov Pharma Announces ADS Ratio Change to Regain Compliance

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken